Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced on October 19, 2026, that zipalertinib achieved a 30.2% intracranial objective response rate in patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion or other uncommon EGFR mutations and active central nervous system metastases. The results come from Cohort C of the Phase 2 REZILIENT2 trial, which enrolled 59 patients and included 43 who were evaluable for intracranial response. Among the evaluable patients, 72.1% achieved intracranial disease control, while median duration of intracranial response reached 9.7 months. The findings will be presented at the European Society for Medical Oncology Congress in Madrid on October 26.
The investigational oral EGFR inhibitor was administered at 100 mg twice daily to patients with active CNS disease, including individuals with leptomeningeal involvement and previous exposure to EGFR-targeted therapies. In the 43-patient evaluable population, 29 had EGFR exon 20 insertion mutations, while the remaining patients had other uncommon EGFR alterations. The median number of previous treatment lines was two, and approximately 44% had received an EGFR tyrosine kinase inhibitor before entering the study.
The CNS findings extend a broader zipalertinib development programme that has already produced positive Phase 3 evidence in first-line lung cancer. In September 2026, the randomized REZILIENT3 study demonstrated that adding zipalertinib to platinum-based chemotherapy improved median progression-free survival to 14.5 months, compared with 8.5 months for chemotherapy alone. Separately, an application for zipalertinib monotherapy in previously treated EGFR exon 20 insertion-mutated lung cancer remains under FDA review, with a target decision date of February 27, 2027.
However, the latest intracranial analysis is a single-arm study and does not establish that zipalertinib is superior to other available treatments for patients with brain metastases. The response figures also apply to the 43 evaluable patients rather than all 59 enrolled participants. The results provide evidence of clinically relevant CNS activity, but further comparative studies and longer follow-up will be needed to determine whether that activity translates into improved neurological outcomes and survival.
Why are active CNS metastases difficult to treat in EGFR-mutated lung cancer?
Non-small cell lung cancer can spread from the lungs to the brain and other parts of the central nervous system. These metastases may cause headaches, seizures, neurological deficits or other complications, although some patients initially have few symptoms. Their presence can complicate treatment because cancer control is required both inside and outside the CNS.
The blood-brain barrier presents an additional challenge. This specialized interface limits the movement of many circulating substances into brain tissue, making it difficult for some systemic medicines to achieve sufficient exposure at intracranial tumor sites. The ability of a targeted therapy to control tumors elsewhere in the body therefore does not automatically establish that it can treat active brain metastases.
EGFR exon 20 insertion mutations represent a distinct molecular subgroup of lung cancer. These alterations differ from the more common EGFR exon 19 deletions and exon 21 L858R substitutions, which are associated with sensitivity to several established EGFR inhibitors. Patients with exon 20 insertions have historically had fewer effective targeted treatment options.
Active CNS metastases also create challenges in clinical research. Some pivotal oncology trials exclude patients with untreated or unstable brain lesions, meaning the resulting efficacy findings may not directly apply to patients with active intracranial disease. Studies specifically enrolling these patients can therefore provide evidence that is not available from broader registration programmes.
REZILIENT2 Cohort C was designed to address this gap by prospectively evaluating zipalertinib in a population with active CNS metastases. However, its nonrandomized design means the findings establish treatment activity without proving comparative benefit.
What does the 30.2% intracranial response rate actually establish?
The study evaluated intracranial response using Response Assessment in Neuro-Oncology Brain Metastases criteria, commonly abbreviated RANO-BM. These criteria provide a standardized approach to evaluating brain metastasis outcomes, including changes in measurable lesions and relevant clinical factors. They differ from the RECIST criteria commonly used to measure systemic solid tumors.
Among 43 evaluable patients, the intracranial objective response rate was 30.2%. This corresponds to approximately 13 patients achieving a qualifying intracranial response. The reported 95% confidence interval ranged from 17.2% to 46.1%, indicating substantial uncertainty around the point estimate.
The confidence interval is important because the analysis population was relatively small. Although the observed response rate supports meaningful biological activity, the true response proportion in a broader comparable population could differ considerably. The finding should not be presented as proof that approximately one-third of all patients with EGFR-mutated brain metastases will respond.
The company also reported a 72.1% intracranial disease control rate. This corresponds to approximately 31 of the 43 evaluable patients and includes responses together with disease stabilization under the study’s assessment criteria. The result suggests that additional patients experienced control of intracranial disease without meeting the stricter threshold for objective response.
Disease control is clinically relevant, but it is not synonymous with tumor shrinkage. Stable intracranial disease may be valuable in selected patients, especially when treatment options are limited, yet the duration and clinical consequences of stability remain important.
Why does the 9.7-month intracranial response duration matter?
Taiho and Cullinan reported a median intracranial duration of response of 9.7 months. The 95% confidence interval extended from 3.3 months to an upper boundary that could not yet be estimated. These findings indicate that some intracranial responses persisted for a substantial period, although the data remain subject to ongoing follow-up.
Duration of response is especially relevant in brain metastasis treatment because an initial reduction in lesion size may be followed by progression. A sustained response could potentially reduce the need for additional local interventions or help maintain neurological function. However, the study does not establish that such benefits occurred consistently among the treated patients.
The median follow-up for the full Cohort C population was 9.2 months at the data cutoff. This is an important qualification because response-duration estimates depend on how long individual patients have been observed and how many remain in response. Continued follow-up could change the estimated median or narrow its uncertainty.
Intracranial response duration also differs from overall progression-free survival. A patient may experience sustained control of brain lesions while disease progresses elsewhere in the body. Conversely, systemic cancer control may continue despite CNS progression. These outcomes need to be evaluated separately.
The 9.7-month result supports the possibility of prolonged brain metastasis activity, but it does not establish an overall survival advantage or eliminate the need for CNS monitoring.
What did the study show among patients without previous EGFR inhibitor treatment?
Of the 43 patients evaluable for intracranial response, 24 had not received a previous EGFR tyrosine kinase inhibitor. In this subgroup, zipalertinib achieved an intracranial objective response rate of 37.5%. That corresponds to approximately nine patients meeting the defined response criteria.
This result is numerically higher than the 30.2% rate across the complete evaluable cohort. It suggests that prior exposure to targeted EGFR therapy could influence treatment outcomes. However, the trial was not randomized according to previous EGFR inhibitor use, and the subgroup was small.
Patients who have not received an EGFR inhibitor may differ from previously treated patients in several ways. Their tumors may have different resistance characteristics, treatment histories and disease burdens. These differences can affect response independently of the medicine being studied.
Approximately 44% of the evaluable population had received prior EGFR-directed treatment. The announcement does not provide a complete response analysis for every previous-treatment subgroup. It would therefore be inappropriate to calculate a definitive response rate for all previously treated patients or to conclude that prior therapy explains the difference.
The data support further investigation into treatment sequencing, but the optimal position of zipalertinib relative to other EGFR-directed medicines remains to be established.
Why are the nine patients with leptomeningeal disease important?
The intracranial evaluable population included nine patients with leptomeningeal disease, a condition in which cancer cells affect the membranes surrounding the brain and spinal cord. Leptomeningeal involvement can cause neurological symptoms across multiple locations and is often associated with a serious prognosis. It can also be challenging to measure through conventional tumor imaging.
Including such patients increases the clinical relevance of the cohort because individuals with leptomeningeal disease are frequently excluded from conventional oncology trials. The study therefore addresses a population in which the evidence supporting systemic treatments can be particularly limited. This is an important feature of the trial design.
However, the October announcement does not disclose a separate response rate, disease control rate or survival estimate for the nine participants with leptomeningeal involvement. Their inclusion within the broader evaluable population should not be interpreted as proof that zipalertinib is effective specifically against leptomeningeal disease.
The biology and assessment of leptomeningeal involvement differ from those of measurable brain parenchymal metastases. Imaging findings, neurological examinations and cerebrospinal fluid assessments may all contribute to clinical evaluation. Demonstrating meaningful benefit may therefore require disease-specific endpoints and follow-up.
The current findings justify further examination of this subgroup while leaving the magnitude of any leptomeningeal treatment effect unresolved.
How does zipalertinib target EGFR exon 20 insertion mutations?
Zipalertinib, previously known as CLN-081 and TAS6417, is an orally administered irreversible EGFR tyrosine kinase inhibitor. It was designed to inhibit EGFR variants carrying exon 20 insertion mutations while maintaining selectivity relative to normal EGFR signaling. This selectivity is important because inhibition of normal EGFR can contribute to adverse effects involving the skin and gastrointestinal system.
EGFR exon 20 insertions create structural changes that can affect how the receptor responds to conventional targeted medicines. Some inhibitors effective against common EGFR mutations have limited activity against particular exon 20 insertion variants. Drug development therefore requires molecules capable of interacting effectively with these altered receptor structures.
Zipalertinib is intended to address this molecular subgroup while potentially reducing certain adverse effects associated with less selective EGFR inhibition. However, selectivity established in laboratory experiments does not guarantee the absence of treatment-related toxicity. Clinical dosing and exposure remain important.
The medicine’s oral route may provide practical advantages compared with infusion-based treatments. Nevertheless, administration convenience alone does not establish superior clinical efficacy, particularly in patients with active CNS disease. The relative value of treatment depends on tumor control, tolerability and patient circumstances.
The new REZILIENT2 analysis provides human evidence that the drug can produce measurable effects in patients with intracranial disease. It does not directly measure drug concentrations in brain tumors or establish the precise relationship between CNS exposure and response.
What safety findings emerged from the CNS metastasis cohort?
Patients in Cohort C received zipalertinib at 100 mg twice daily. The companies reported that the medicine was generally well tolerated in the evaluated population, although treatment-related adverse events occurred. The most commonly reported events included paronychia, affecting 32.6% of patients, and diarrhea, affecting 25.6%.
Paronychia involves inflammation around the nails and is a recognized adverse effect of some EGFR-targeted medicines. Diarrhea can also occur because EGFR signaling contributes to normal gastrointestinal function. The presence of these reactions demonstrates that the medicine’s intended mutant selectivity does not eliminate all effects associated with EGFR inhibition.
Grade 3 or higher treatment-related adverse events were reported in nine patients, corresponding to 20.9% of the 43-patient evaluable population described in the safety summary. Acneiform dermatitis accounted for approximately 4.7%. The announcement does not provide a complete breakdown of treatment interruptions, dose reductions or adverse-event-related discontinuations.
Patients with brain metastases may also require supportive medicines, including corticosteroids or treatments for neurological symptoms. Such factors can influence tolerability and the interpretation of adverse events. The summary does not provide sufficient detail to establish how those circumstances affected the observed safety profile.
The findings support further clinical development, but the small population and relatively short follow-up cannot exclude uncommon or delayed toxicities. Larger studies and continued monitoring will be necessary.
How do the CNS findings relate to zipalertinib’s positive Phase 3 results?
The REZILIENT2 CNS study forms part of a larger clinical development programme that includes the randomized Phase 3 REZILIENT3 trial. REZILIENT3 evaluated zipalertinib plus platinum-pemetrexed chemotherapy against chemotherapy alone in previously untreated advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
At the September 2026 interim analysis, 279 patients had been randomized following an initial safety lead-in. Median progression-free survival was 14.5 months with the zipalertinib combination, compared with 8.5 months for chemotherapy alone. The hazard ratio was 0.50, with a statistically significant p-value of 0.00015.
The objective response rate was also higher with the combination, reaching 65.0% compared with 40.3% in the control group. Median duration of response was 14.2 months versus 9.9 months. These findings provide randomized evidence that adding zipalertinib to chemotherapy improves disease control in the studied first-line population.
Importantly, approximately 31% of patients in each randomized arm had brain metastases at baseline. The reported progression-free survival benefit was consistent in the subgroup with brain metastases, with a hazard ratio of 0.38. However, that subgroup result should not be confused with the directly measured intracranial response rate from REZILIENT2 Cohort C.
The two studies evaluate different treatment approaches and populations. REZILIENT3 investigates zipalertinib plus chemotherapy in the first-line setting, while REZILIENT2 Cohort C evaluates zipalertinib monotherapy in patients with active CNS disease and varying previous treatments. Their results are complementary but cannot be combined into one efficacy estimate.
What is the current FDA regulatory status of zipalertinib?
Taiho Oncology, Taiho Pharmaceutical and Cullinan announced on April 28, 2026, that the FDA had accepted a New Drug Application for zipalertinib monotherapy. The application covers patients with locally advanced or metastatic EGFR exon 20 insertion-mutated non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy, with or without previous amivantamab treatment. The FDA assigned a target action date of February 27, 2027.
The application is supported by results from the Phase 2b REZILIENT1 study. It is separate from the new REZILIENT2 CNS analysis, which evaluates a broader population including other uncommon EGFR mutations. Positive intracranial results therefore do not automatically expand the indication being considered under the existing application.
Zipalertinib also received FDA Breakthrough Therapy designation in 2022 for previously treated EGFR exon 20 insertion-mutated advanced lung cancer. The designation may support more intensive regulatory interaction but does not authorize marketing. As of October 20, 2026, zipalertinib remains investigational.
The companies are also pursuing a regulatory strategy for the first-line combination supported by REZILIENT3. The FDA has accepted the programme into its Real-Time Oncology Review initiative, with completion of the associated application planned before the end of 2026. That process is distinct from the February 2027 monotherapy decision.
The development programme therefore has several regulatory pathways involving different treatment settings. Clinical findings must be matched to the population and combination covered by each submission.
How could zipalertinib compete with existing EGFR exon 20 treatments?
The treatment landscape for EGFR exon 20 insertion-mutated lung cancer has expanded substantially. Amivantamab, marketed as Rybrevant, is approved with carboplatin and pemetrexed for first-line treatment of eligible advanced disease. It also has an approved role as monotherapy following platinum-based chemotherapy.
Sunvozertinib, marketed as Zegfrovy, received FDA accelerated approval in July 2025 for eligible patients whose EGFR exon 20 insertion-mutated disease progressed on or after platinum-based chemotherapy. Its authorization established another oral targeted option in the previously treated setting. These developments mean zipalertinib would enter an increasingly competitive market if approved.
Potential differentiation could involve intracranial activity, tolerability, administration characteristics and effectiveness after earlier therapies. The REZILIENT2 CNS findings are relevant because treatment of active brain metastases remains difficult. However, comparing its 30.2% intracranial response rate with systemic response rates from other drug trials would be misleading.
No completed randomized head-to-head study has established that zipalertinib is superior to amivantamab or sunvozertinib for active CNS metastases. Differences in previous treatment, mutation subtype, CNS disease status and response criteria complicate cross-study comparisons. Claims of competitive advantage will require appropriately comparable evidence.
The positive REZILIENT3 findings provide a stronger basis for considering zipalertinib in first-line combination treatment. Nevertheless, that regimen remains investigational and requires regulatory review before commercialization.
What does zipalertinib’s progress mean for Taiho and Cullinan?
Zipalertinib is being developed by Taiho Oncology and its parent Taiho Pharmaceutical in collaboration with Cullinan Therapeutics. Taiho Pharmaceutical is part of Otsuka Holdings, while Cullinan is an independently listed United States biotechnology company. The agreement gives Taiho commercialization responsibility and provides Cullinan with an economic interest in potential future sales.
According to Cullinan’s regulatory filings, the companies share development costs for agreed indications and are each entitled to 50% of future pretax profits from potential United States zipalertinib sales, subject to contractual adjustments. Cullinan is also eligible for specified regulatory milestone payments under a separate arrangement. These prospective financial benefits remain contingent on successful development and regulatory outcomes.
The positive Phase 3 programme and ongoing FDA review create potential commercial opportunities, while the CNS results broaden the clinical evidence supporting continued investigation. However, the October announcement does not provide an updated sales forecast or a regulatory decision concerning CNS disease. The findings should therefore be interpreted as a clinical development milestone rather than a new revenue-generating approval.
For Cullinan, the programme represents an oncology asset alongside its growing focus on immunology and autoimmune disease. For Taiho, zipalertinib could extend its portfolio of orally administered cancer medicines. Both companies remain exposed to regulatory, commercial and competitive uncertainty until approval and market adoption are established.
What must the next studies demonstrate about zipalertinib and brain metastases?
The REZILIENT2 results establish that zipalertinib can produce measurable intracranial tumor responses in selected patients with active CNS disease. However, several questions remain concerning the durability of those responses, their relationship with neurological function and the treatment’s effect on survival. Longer follow-up will help clarify whether initial brain disease control persists.
A critical question is how outcomes vary across EGFR mutation subtypes. The evaluable cohort included 29 patients with exon 20 insertions and 14 with other uncommon EGFR mutations, but the announcement does not disclose a complete response breakdown for each molecular subgroup. Such analyses could help identify patients most likely to benefit.
Previous treatment exposure also requires further investigation. The higher numerical response rate among patients without previous EGFR inhibitors suggests that treatment history may be relevant, but the small, uncontrolled analysis cannot establish a definitive sequencing strategy. Future studies should characterize molecular resistance and the treatment’s effectiveness after other EGFR-directed medicines.
The clinical implications of leptomeningeal involvement remain particularly uncertain. Although nine evaluable patients had this form of CNS disease, the announcement provides no separate efficacy estimate for them. Further studies with appropriate neurological, imaging and survival endpoints will be necessary.
The October 2026 findings add an important dimension to a programme already supported by positive randomized Phase 3 results. Zipalertinib achieved a 30.2% intracranial response rate and 72.1% disease control rate in a difficult-to-treat CNS metastasis population, with median intracranial response duration reaching 9.7 months.
These results support continued evaluation of zipalertinib as a targeted therapy for selected EGFR-mutated lung cancers. However, the evidence remains single-arm and does not establish comparative superiority or an approved CNS-specific indication. The upcoming FDA monotherapy decision, first-line combination review and longer-term CNS data will determine how broadly the medicine may eventually be used.
